Cell-selective drug release Modulation of neuroinflammation in the central nervous system (CNS) holds 20 great promise for the treatment of several neurodegenerative diseasesmany CNS disorders but it is still 21 challenging. However, selective cell targeting remains challenging. We previously exploited 22 demonstrated that polymeric nanoparticles (NPs) injected intra-parenchyma in the brain can be 23 internalized specifically in to obtain cell specific uptake in microglia/macrophages surrounding the 24 injection site, upon intra-parenchyma administration in mice. Here, we explored NPs administration in the 25 cerebrospinal fluid (CSF) to achieve a wider spreading and increased cell targeting throughout the CNS, 26 generated new NPs variants and studied the effect of modifying size and surface charge on NPs 27 biodistribution and cellular uptake. As hypothesized, intra-cerebroventricular administration resulted in a 28 widespread NPs brain distribution throughout the CNS with prevalent localization in proximity to stem-29 cell niches, such as around the lateral ventricles, the subventricular zone and the rostral migratory stream. 30
our attention on hematopoietic myeloid cells (CD45 + either CD11b -or CD11b + ) and on some of the 10
CD45
-cells, by focusing our attention oni.e. astrocytes -identified by positivity for ACSA2 marker [20] , 11 oligodendrocytes -identified through O4 antigen [21] (Fig. 1HG ). The CD45 + CD11b + fraction (microglia) within NPs-containing cells moved 13 from 34-37%40% in the case of EP and SA-SP NPs to about 5060% in the case of smaller sized SA-N1 14
NPs, namely SA-N and SA-SP (Fig.1FG) (Fig. 1H ). All the three tested NPs were internalized in these cells. 20
However, as opposed to EP NPs, the self-assembly smaller sized NPs displayed a tendency to higher 21 uptake by astrocytes, endothelial cells and oligodendrocytes. Strikingly, SA-SP NPs were the only NPs 22 internalized also by a small fraction of Thy1+ neurons and showed a significantly higher uptake by 23 endothelial cells and by O4 + oligodendrocytes. 24
Myeloid hematopoietic cells expressing stemness markers in CNS neurogenic niches can selectively 25 uptake NPs 26
Since the cytofluorimetric immunophenotypic characterization of the NPs + cell types did not account for 27 the totality of the rhodamine + population, we decided to complement this information by using other 28 known markers of glial cells and immunohistochemistry. In this setting, NPs signal was predominantly 29 associated with Iba1 + microglia and CD68 + macrophages scattered throughout the brain parenchyma for 30 all the tested formulations ( Fig. 2A-B ) with no co-localization detected with the GFAP astrocyte marker 31 (Fig. 2C-D) . Interestingly, we detected NPs in a subset of Iba1 + cells that was also positive for Nestin, a 32 NPs can be internalized in CD45 + /c-kit + cells upon ICV administration and mannitol-mediated BBB 24 disruption (in a range spanning between 45% and 75% of total CD45 + /c-kit + population, depending on 25
NPs size and surface charge; Fig. 3I) . 26
In vitro uptake of NPs does not predict the in vivo distribution and uptake profile 27
To interpret the differential CNS bio-distribution of the tested NPs of different size and surface charge, 28
we studied the kinetics and the overall efficiency of their uptake by microglia like cells (BV2 cells, which 29 recapitulate several functional features of murine microglia/macrophages [24]) in vitro. Almost 100% of 30 the cells turned out to be Rh+ short-term (30 min) after incubation with NPs, suggesting that BV2was not fully inhibited by fucoidan, which may be due to some level of receptor-independent uptake that 23 is equally relevant for all the tested NPs. 24
Chemotherapeutic drug loading in NPs benefits their pharmacodynamics 25
We next tested the capability of the NPs obtained via the self-assembly method (that have a greater 26 translational potential) to uptake and release drugs. The neutral 39 nm (SA-N) NP are highly suited for 27 uptake of lipophilic drugs, whereas the negatively charged 37 nm NPs (SA-SP) are more suited for the 28 loading of molecules with an amphiphilic nature. Given these NPs features, we tested two 29 chemotherapeutic compounds, etoposide and busulfan, as prototypic drugs (the former being highly 30 liposoluble, the latter being more amphiphilic). We first measured the loading efficiency of etoposide andbreakes (DSBs) [25] and treatment of cells with busulfan leads to the formation of γH2AX+ foci in cells 20 nuclei that are detectable by histology and flow cytometry. Exposure to both busulfan as free drug at 30 21 µg/ml and to busulfan-loaded NPs resulted in an increased percentage of cells displaying positivity for 22 γH2AX ( Fig. 4D and S4A) . A significantly higher amount of γH2AX + cells was detected when busulfan-23 loaded NPs were employed with a dose dependent effect as shown by both flow cytometry (Fig. 4D) and 24 histology, as γH2AX + nuclear foci (Fig. S4B) . Incubation with scavenger receptor inhibitors was able to 25 prevent the effect exerted by busulfan encapsulated in NPs (Fig 4E) , further confirming that the observed 26 improved drug efficacy of the NP formulation was due to the encapsulation of the drugs within the NPs. 27 Similar results were obtained by loading etoposide in SA-N NPs. As shown in Fig. 4F , with SA-N empty 28
NPs we did not retrieve significant toxicity at any time-point of analysis and even at the highest tested 29 concentrations. When etoposide was loaded in NPs, it determined cell death already after 24 hours of 30 incubation at a level similar to the one of the not encapsulated drug. However, after 72 hours of 31 incubation, the toxicity observed with etoposide-loaded NPs tested at the lowest concentration was greater 32 than the one observed with the not encapsulated drug, suggesting that also the encapsulation of etoposidein NPs enhances its efficacy, determining an improvement of the cytotoxicity of the drug already at very 1 low concentrations. 2
Controlled chemotherapeutic delivery and selective targeting of CNS resident microglia 3
Hematopoietic stem cell (HSC) progeny can represent a vehicle for therapeutic molecule delivery to the 4 CNS upon their transplantation in myeloablated hosts [11] . CNS delivery of therapeutics by means of 5 HSC-derived cells depends on the engraftment in the recipients' CNS of donor myeloid cells producing 6 the molecule of therapeutic relevance. Instrumental for inducing and fostering this cell engraftment in the 7 CNS after HSC transplantation is the use of busulfan, that is likely affecting a fraction of microglia and/or 8 their endogenous progenitors [26] . We reasoned that the NPs characterized in this work could be 9
exploited to obtain controlled busulfan delivery in the CNS. As first step towards this goal, we evaluated 10 the brain penetration and pharmacodynamics of busulfan upon systemic administration at a myeloablative 11 dose (i.e. 25 mg/kg/day, usually administered for 4 consecutive days [26] ) to obtain a reference exposure 12
for NPs-mediated busulfan delivery. Busulfan was administered i.p. (single administration), then animals 13 were sacrificed at different time-points post-dosing to collect plasma and brain samples for a 14 pharmacokinetic analysis. Busulfan reached maximal concentration in the plasma and in the brain at 15 15 and 30 minutes post-administration, respectively (Fig. 5A) . Afterwards, it was rapidly washed out from 16 both compartments with a very similar rate of clearance, resulting in half-life of 137 minutes in plasma 17 and of 133 minutes in the brain (see Table 2 ). This rapid partitioning of busulfan between plasma and 18 brain may reflect the amphiphilic features of the compound, which is known to have also good blood 19 brain barrier permeability. Based on these data, considering that the actual dose of administered busulfan 20 for a mouse of 20 g of body weight would be 500 µg, the total brain exposure to the drug (during the 480 21 minutes of observation for this experiment) is about 31.6 µg (the weight of the brain for a 20 g mouse isabout 400-500 mg). This corresponds to only about 6.3% of the dose administered systemically reaching 23 the brain. We next identified in the brain the areas where busulfan exerted its effect by γH2AX staining in 24 animals exposed to a fully myeloablative dosing [26] and analyzed 1 and 5 days after the last busulfan 25 dose. γH2AX was hardly detectable in untreated control mice (Fig. 5B) , except for few γH2AX + foci 26 found in neuronal cells, mainly localized in the hippocampal region, in line with literature evidences 27 demonstrating a correlation between physiological neuronal activity and H2AX phosphorylation in the 28 hippocampus of healthy mice [27] . On the contrary, in busulfan-treated mice γH2AX
+ signal was present 29 in nuclei of cells lining the lateral ventricles or located in the SVZ and rostral-migratory stream (Fig. 5B,  30 inset). γH2AX immunoreactivity was already present one day after the last dosing and became more 31 pronounced and diffuse at day 5 after the last administration, with positive cells spread throughout the 32 brain, including hippocampus, cortex, hypothalamus and cerebellar nuclei (not shown). γH2AX + foci 33 were present both in neurons and glial cells, i.e. microglia and astrocytes (Fig. 5C ). We next explored the 1 possibility to reproduce the same pharmacodynamics and pharmacokinetic effects by administering 2 busulfan in its clinical-grade formulation (i.e. Busilvex) directly in the brain ventricles at a dose of 3 30µg/mouse equivalent to brain exposure after systemic drug delivery. The drug administered 4 monolaterally ( Fig. S5A ) rapidly distributed throughout the brain within 5 minutes post administration, 5 but its total concentration dropped of almost 70% during the following 15 minutes (Fig. S5B ). Moreover, 6 despite the drug was administered only in the brain, it could be detected in the plasma already 5 minutes 7 after ICV administration, suggesting a leakage of this drug formulation out of the brain. Notably, daily 8 ICV administration of busulfan for four days, to mimic the overall total brain exposure achieved by 9 systemic busulfan myeloablative regimens, resulted in very few γH2AX + foci localized only in the areas 10 lining the lateral ventricles ( µg/mouse/day, a substantial increase of γH2AX signal over the basal was observed with robust γH2AX 16 staining found within microglia of the treated mice (Fig.6A ). This is remarkable, as the busulfan dose that 17 we could test with the NPs formulation (5µl injected bilaterally of a NPs suspension containing busulfan 18 at ~0.3µg/µl, corresponding to ~3µg busulfan/mouse) was lower than the reference brain exposure 19 achieved with systemic administration (31.6 µg), due to technical limitations. The γH2AX signal was 20 spread throughout the brain, with high intensity in the subventricular zone, cortex and areas lining the 21 lateral and fourth ventricles (Fig. 6B ). Signal distribution was superimposed to the bio-distribution of the 22 rhodaminated NPs that were spread throughout the brain parenchyma, with high density of signal in the 23 areas surrounding the lateral ventricles and the fourth ventricle (Fig. S2B) . Unexpectedly, by 24 immunohistochemistry we could detect Iba1 + microglia cells that stained positive for NPs but were 25 negative for γH2AX (arrows in Fig. 6C-D) , as well as cells that were negative for NPs but had γH2AX 26 signal in the nucleus (arrowheads in Fig. 6C-D) , suggesting potential rapid release of the drug by the NPs, 27
i.e. before internalization into the cells. Of note, no acute toxicity nor neuroinflammation were detected 28 after 4 busulfan-loaded NPs (SA-SP-BUS NPs, Table 1 ) administrations. 29
The physicochemical properties of the compound loaded in NPs influence dramatically the loading 30 efficiency and the release profile; thus, the loading of a highly lipophilic drug is predicted to be more 31 efficient and the release to be slower, as compared to an amphiphilic compound. In order to achieve a 32 better and more specific killing of cells targeted by NPs, we replaced the NPs formulation containing 33 highlighted by γH2AX staining) and it was detected also in cells that were negative for NPs. The NPs 24 developed by our group are very well suited for uptake and release of lipophilic compounds. Since 25 busulfan is an amphiphilic molecule, it can be hypothesized that the release from NPs in vivo occurs more 26 rapidly than etoposide, as observed also by other authors in vitro in PBS [42] , which may explain the 27 more widespread effect observed upon CSF administration of busulfan loaded NPs. Nevertheless, the 28 encapsulation of busulfan into SA-SP NPs increased its pharmacodynamic profile, since we could retrieve 29 a significant increase of γH2AX+ signal in microglia cells at a lower dose as compared to the one needed 30 to achieve a similar effect by systemic administration. This is in line with our previous observations 31
showing an improved pharmacological profile of an anti-inflammatory drug (i.e. minocycline) loaded in 32 PCL-based NPs [7] . Moreover, busulfan loaded into NPs displayed an improved safety profile, as 33 compared to the toxicity observed by employing the free clinical grade drug formulation (i.e. Busilvex). 
